Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AS1404 with Docetaxel in Hormone Refractory Metastatic Prostate Cancer
NCT00111618Phase 2Completed
- Sponsor
- Antisoma
- Start
- May 2005
- Primary completion
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vadimezan in prostate cancer (PCa) (2 arms), sponsored by Antisoma. Primary endpoints: Laboratory safety and Adverse event monitoring, Electrocardiogram and 6 more. Started May 2005; status: completed.
02
Drugs
vadimezan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00111618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00111618.